The clinical impact of interferon beta antibodies in relapsing-remitting MS

Journal of Neurology

Volumn 251, Issue 3, 2004, Pages 305-309

  Perini, Paola ^a   Calabrese, Massimiliano ^a   Biasi, Giovanni ^b   Gallo, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

EDSS; Interferon beta; Multiple sclerosis; Neutralizing antibodies; Relapse rate

Indexed keywords

BETA1A INTERFERON; INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HASHIMOTO DISEASE; HUMAN; IMMUNOTHERAPY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; SKIN NECROSIS; SPASTICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES; FEMALE; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; STATISTICS, NONPARAMETRIC;

EID: 1642277003     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-0312-8     Document Type: Article

References (22)

1. The IFNβ Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
2. The IFNβ Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
3. Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
4. The IFNβ Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47:889-894
5. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504
6. The PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group and The University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628-1636
7. Rudick RA, Simonian NA, Alam JA et al. (1998) Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272
8. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56:1496-1504
9. Li DKB, Zhao GL, Paty DW and The University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56:1505-1513
10. Pachner AR (1997) Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology 49:647-650
11. Rice G (2001) The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 58:1297-1298
12. Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC (1989) Evaluation of neutralizing antibodies in patients treated with recombinant interferon beta. J Interferon Res 9(suppl 1):S51-S60
13. Perini P, Facchinetti A, Bulian P et al. (2001) Interferon-beta (IFN-β) antibodies in interferon-β1a- and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur Cytokine Netw 12:56-61
14. Kivisäkk P, Alm GV, Tian WZ, Matusevicius D, Fredrikson S, Link H (1997) Neutralizing and binding anti-interferon-β-1b (IFNβ1b) antibodies during IFNβ1b treatment of multiple sclerosis. Mult Scler 3:184-190
15. Kivisäkk P, Alm GV, Fredrikson S, Link H (2000) Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β-1a and IFN-β-1b treatment in multiple sclerosis. Eur J Neurol 7:27-34
16. Antonelli G, Simeoni E, Bagnato F et al. (1999) Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 168:131-136
17. Bertolotto A, Malucchi S, Sala A et al. (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148-153
18. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G (1999) The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology 52:1277-1279
19. Antonelli G, Bagnato F, Pozzilli C et al. (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res 18:345-350
20. Fierlbeck G, Schreiner T (1994) Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-β. J Interferon Res 14:205-206
21. Fernández O, Mayorga C, Luque G et al. (2001) Study of binding and neutralising antibodies to interferon-b in two groups of relapsing-remitting multiple sclerosis patients. J Neurol 248:383-388
22. Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, Thompson A, Petkau J, Miller D, for the European Study Group in Interferon betalb in secondary progressive MS (2003) Neutralizing antibodies during treatment of secondary progressive MW with IFNβ1b. Neurology 60:37-43